214287-92-0 Usage
General Description
(4S)-5,6-difluoro-4-(3-methylbut-1-yn-1-yl)-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one is a chemical compound belonging to the class of dihydroquinazolinones. It is a highly fluorinated compound with a unique structure and is often used as a building block for the synthesis of various pharmaceuticals and agrochemicals. The presence of fluorine atoms in the molecule makes it highly attractive for medicinal chemistry, as fluorinated compounds are known for their improved bioavailability, metabolic stability, and interaction with biological targets. The specific stereochemistry of the compound, designated as (4S), refers to the arrangement of substituents around the chiral center at the fourth position of the molecule. (4S)-5,6-difluoro-4-(3-methylbut-1-yn-1-yl)-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one has the potential for various applications in drug discovery and agrochemical research due to its unique structure and fluorinated nature.
Check Digit Verification of cas no
The CAS Registry Mumber 214287-92-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,4,2,8 and 7 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 214287-92:
(8*2)+(7*1)+(6*4)+(5*2)+(4*8)+(3*7)+(2*9)+(1*2)=130
130 % 10 = 0
So 214287-92-0 is a valid CAS Registry Number.
214287-92-0Relevant articles and documents
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors
Corbett, Jeffrey W.,Ko, Soo S.,Rodgers, James D.,Gearhart, Lisa A.,Magnus, Nicholas A.,Bacheler, Lee T.,Diamond, Sharon,Jeffrey, Susan,Klabe, Ronald M.,Cordova, Beverly C.,Garber, Sena,Logue, Kelly,Trainor, George L.,Anderson, Paul S.,Erickson-Viitanen, Susan K.
, p. 2019 - 2030 (2007/10/03)
A series of 4-alkenyl and 4-alkynyl-3,4-dihydro-4-(trifluoromethyl)-2- (1H)-quinazolinones were found to be potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) of human immunodeficiency virus type-1 (HIV-1). The 4-alkenyl-3,4-dihydro-4-(triflu
Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1
Corbett, Jeffrey W.,Ko, Soo S.,Rodgers, James D.,Jeffrey, Susan,Bacheler, Lee T.,Klabe, Ronald M.,Diamond, Sharon,Lai, Chii-Ming,Rabel, Shelley R.,Saye, Jo Anne,Adams, Stephen P.,Trainor, George L.,Anderson, Paul S.,Erickson-Viitanen, Susan K.
, p. 2893 - 2897 (2007/10/03)
A research program targeted toward the identification of expanded- spectrum nonnucleoside reverse transcriptase inhibitors which possess increased potency toward K103N-containing mutant human immunodeficiency virus (HIV) and which maintain pharmacokinetic
